Investigations on bone metabolism of urological tumors forming metastases

Urologia Internationalis

Volumn 56, Issue 2, 1996, Pages 61-68

  Bichler, K H ^a   Petri, E ^a   Hub, A ^a   Kleinknecht, A ^a   Heidenreich, A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Alkaline phosphatase; Bone metabolism; Bone metastases; Hydroxyproline; Ostase; Osteocalcin; Osteodensitometry; Pyridinium crosslinks

Indexed keywords

ALKALINE PHOSPHATASE; HYDROXYPROLINE; MARKER; OSTEOCALCIN; PHOSPHATASE; PYRIDINIUM DERIVATIVE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD LEVEL; BONE ATROPHY; BONE METABOLISM; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DENSITOMETRY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; MALE; MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; SERODIAGNOSIS; SYMPTOM; URINARY TRACT CANCER;

EID: 0030040567     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282813     Document Type: Article

References (38)

1. Jacobs SC: Spread of prostatic cancer to bone. Urology 1983;21:337-344.
2. Cumming J, Hacking N, Fairhurst J, Ackcry D, Jenkins JD: Distribution of bony metastases in prostatic carcinoma. Br J Urol 1990:66:411-414.
3. Levy MH: Pain management in advanced cancer. Semin Oncol 1985;12:394-410.
4. Scher HI, Yagoda A: Bone metastases: Pathogenesis. treatment and rationale for use of resorption inhibitors. Am J Med 1987;82:6-28.
5. Zöfel P: Statistik in der Praxis (1993) ed 3. UTB 1293.
6. Doyle GM, Mohler JL: Prediction of metastatic potential of aspirated cells from the Dunning R-3327 prostatic adenocarcinoma model. J Urol 1992;147:756-759.
7. Manishen WJ, Sivananthan K, Orr FW: Re-sorbing bone stimulates tumor cell growth. A role for the host microenvironment in bone metastasis. Am J Med 1986;123:39-45.
8. Fidler IJ, Radinsky R: Genetic control of cancer metastasis. J Natl Cancer Inst 1990:82: 166-168.
9. Seibel MJ: Hydroxy-Pyridinium -'Crosslinks' im Urin als spezifischer Marker der Knochenresorption bei metabolischen Knochenerkrankungen. Klin Lab 1992;38:642-643.
10. Haberkamp M, Allolio B: Indikationen zur Knochendichtcmcssung. Med Klinik 1992:87: 131-137.
11. Khaw KT, Sneyd MJ, Compston J: Bone density parathyroid hormone and 25-hydroxyvitam-in D concentrations in middle-aged women. BMI 1992:305-273-277.
12. Aloia JF, Vaswani A, Yek JK, Ellis K, Yasumlira S, Cohn SH: Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988: 84:401-408.
13. Moran J, Hunziker W, Fischer JA: Calcitonin and calcium ionophores: Cyclic AMP responses in cells of a human lymphoid line. Proc Natl Acad Sei USA 1978:75:3984-3988.
14. Raue F, Schneider HG, Grauer A: Diagnostische Bedeutung der Peptide der Calcitonin-Familie. Ärztl Lab 1988;34:271-277.
15. Moss DW: Aspects of the relationship between liver, kidney and bone alkaline phosphatases; in Stigbrand T. Fishman WH (eds): Human Alkaline Phosphatases. New York. Liss. 1985. pp 79-86.
16. Fishman WH: Alkaline phosphatase isoenzymes: Recent progress. Clin Biochem 1990: 23:99-104.
17. Whyte MP: Alkaline phosphatase and the measurement of bone formation; in Potts JT. Frame B (eds): Clinical Disorders of Bone and Mineral Metabolism. Amsterdam. Exccrpta Medica. 1983. p 120.
18. Van Straalcn JP, Sanders E, Prummel MF, Sanders GTB: Bone alkaline phosphatase as indicator for bone formation. Clin Chim Acta 1991;201:27-34.
19. Duda RJ Jr, O'Brien JF, Katzman JA, Peterson JM, Mann KG, Riggs BL: Concurrent assays of circulation bone gla protein and bone alkaline phosphatase: Effects of sex. age and metabolic bone disease. J Clin Endocrinol Metab 1988; 66:951-957.
20. Epstein S: Serum and urinary markers of bone remodeling: Assessment of bone turnover. En-docrRev 1988:9:437-449.
21. Arai Y, Takeuchi H, Oishi K, Yoshida O: Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 1992:20:169-177.
22. Johansen JS, Riis BJ, Dclmas PD, Christiansen C: Plasma BGP. an indicator of spontaneous bone loss and of the effect of oestrogen treatment in post-menopausal woman. Eur J Clin Invest 1988:18:191-195.
23. Mcnon RK, Gill DS, Thomas M, Kernoff PBA, Dandona P: Impaired carboxylation of osteocalcin in warfarin-treated patients. J Clin Endocrinol Metab 1987;64:59-61.
24. Brown JP, Malaval L, Chapuy MC, Delrnas PD, Edouard C, Meunier PJ: Serum bone gla protein: A specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984: i: 1091-1093.
25. Priee PA, Parthemore JG, Deftos LJ: New biological marker for bone metabolism: Measurements by radioimmunoassay of bone gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980: 66:878-883.
26. Gundberg CM, Wilson PS, Gallop PM, Parfitt AM: Determination of osteocalcin in human serum: Results with two kits compared with those by a well-characterized assay. Clin Chem 1985;31:1720-1273.
27. Dclmas PD: Serum bone gla protein compared to bone histomorphomctry in endocrine diseases. Bone 1985:6:339-341.
28. Stracke H, Schatz CH, Pralle H, Ullmann J, Schatz II: Osteocalcin, ein Marker bei Erkrankungen mit erhöhtem Knochenumsatz. Dtsch Med Wochenschr 1985;38:1442-1446.
29. Kuhlcncordt F, Ringe JD, Kruse HP: Behandlung der Osteodystrophia deformans Paget mit Lachs-Calcitonin. Dtsch Med Wochenschr 1985;106:1620-1623.
30. Stracke H, Schulz A, Weber U, Ullmann J, Schatz H: Osteocalcin und Knochenhistologic bei Osteoporose. Klin Wochenschr 1987:65: 1095-1100.
31. Baltaci S, Sarica K, Beduk Y, Yaman LS: Serum osteocalcin levels in patients with prostatic carcinoma. Euro-American Conference on Urological Cancer, Athens. Sept 1992.
32. Bichlcr KH, Harzmann R, Heller W, Wilms K, Delling G, Schmidt KH: Diagnostik ossärer Metastasen des Prostatacarcinoms. Aktuel Urol 1978:9:21-28.
33. Bishop MC, Fellows GJ: Urine hydroxyproline excretion -A marker of bone metastases in prostatic carcinoma. Br J Urol 1977:49:711-716.
34. Clarke NW, Holbrook IB, McClure J, George NJR: Osteoclast inhibition by pamidronatc in metastatic prostate cancer: A preliminary study. Br J Cancer 1991:63:420-423.
35. Dclmas PD: Biochemical markers of bone turnover: Methodology and clinical use in osteoporosis. Am J Med 1991:91 (suppl 5B):59-63.
36. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ: Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991:21:310-315.
37. Delrnas PD, Gineyts F, Bertholin A, Garnero P, Marchand F: Immunoassay of pyridinolinc crosslink excretion in normal adults and in Paget's disease. J Bone Min Res 1993:8:643-648
38. Ucbc'hart D, Gineyts E, Chapuy MC, Delrnas PD: Urinary excretion of pyridinium crosslinks: A new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.